Description: Consequently, in 1998, the GEICAM 9805 trial was initiated to compare the effects of FAC with TAC in patients with high-risk, node-negative breast cancer as defined according to the St. Gallen ...
DA: 60 PA: 3 MOZ Rank: 8
Description: Poster in ASCO 2004 Martin M, Lluch A, Seguí MA, Antón A, Ruiz A, Ramos M, Rodríguez-Lescure A, Adrover E. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study. 40th ASCO Annual Meeting.
DA: 91 PA: 42 MOZ Rank: 12
Description: GEICAM 9805 studied the efficacy of Taxotere against another chemotherapy drug called fluorouracil (Adrucil). Both drugs were applied in combination with other chemo drugs called doxorubicin and cyclophosphamide. The clinical could be considered a success in proving the effectiveness of Taxotere in reducing tumor size and achieving remission.
DA: 32 PA: 39 MOZ Rank: 95
Description: for the GEICAM 9805 Investigators * Additional investigators who participated in the Spanish Breast Cancer Research Group (GEICAM) study are listed in the Supplementary Appendix, ...
DA: 40 PA: 93 MOZ Rank: 19
Description: TAC versus FAC as Adjuvant Chemotherapy for High-risk Node-negative Breast Cancer: Results from the GEICAM 9805 Trial Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M,
DA: 3 PA: 44 MOZ Rank: 35
Description: Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial
DA: 64 PA: 78 MOZ Rank: 23
Description: + geicam 2011 - geicam 2011 Poster en GEICAM 2011. Aranda FI, Sánchez- Tejada L, Muci T, Alenda C, Peiró G, Seguí J, Niveiro M, Payá a, Laforga JB, de Álava E, Palacio J, Munárriz B, Ruíz- Borrego JM, García AM, Escuder JM, Martin M. Análisis de mutaciones de PIK3CA en carcinomas de mama con ganglios linfáticos positivos (GEICAM 9906 ...
DA: 17 PA: 14 MOZ Rank: 52
Description: Methods. We performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003–02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments.
DA: 62 PA: 79 MOZ Rank: 9
Description: Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study
DA: 47 PA: 20 MOZ Rank: 26
Description: Another Spanish trial (GEICAM-9805) was published in 2010 which investigated the benefit of adding adjuvant taxanes in node-negative breast cancer patients, and its arms were identical to the BCIRG-001 arms. But, unlike the BCIRG trial it allowed primary G-CSF prophylaxis in its TAC arm which greatly declined the rate of NF in contrast to the ...
DA: 59 PA: 84 MOZ Rank: 65